Triple-Drug attack shows promise for tough breast cancer
NCT ID NCT01872260
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tests two new drugs (LEE011 and BYL719) combined with a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the combination can better control the disease. Participants have cancer that has spread or cannot be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital SC-5
Boston, Massachusetts, 02114, United States
-
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas, 78229, United States
-
Northwest Medical Specialties
Tacoma, Washington, 98405, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Parkville, Victoria, 3050, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Pisa, PI, 56126, Italy
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Bellinzona, 6500, Switzerland
-
Novartis Investigative Site
Glasgow, G12 0YN, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Texas Oncology
Amarillo, Texas, 79124, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Univ of California at San Diego Moores Cancer Ctr
San Diego, California, 92103, United States
-
Vanderbilt University Medical Ctr
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.